Bank Of America Names GWPH Top SMid-Cap Biotech For 1H19 As Firm Notes 'continued strong feedback from prescribing physicians on the new Epidiolex launch' And Firm Is Confident 'in the long term potential for sales in' Dravet And Lennox-Gastaut Syndrome